Immunomodulatory effect of cyclophosphamide on host humoral immunity in Dunning's R-3327 adenocarcinoma of the prostate View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1991-02

AUTHORS

R. Bhatti, P. Ray, N. Bell

ABSTRACT

The object of the present investigations was delineation of the exclusive effects of cyclophosphamide (Cytoxan) on host humoral response to tumor, as evaluated by the level of circulating antigen/antibody complexes (AACs), which may reflect the chemo-responsiveness of hosts and provide a rationale for new therapeutic strategies. Our data, recorded in CopenhagenxFischer rats bearing Dunning's R-3327 Mat Ly-Lu adenocarcinoma of the prostate, show no modulatory effect of cyclophosphamide at 10 mg/kg, a nonspecific immunosuppressive effect at 30 mg/kg, and a definite immunostimulatory effect on host humoral immunity at 100 mg/kg. Sequential determination of AAC levels at different stages of tumor growth, i.e. from the primary to the metastatic stage, performed with the original purpose of demonstrating that any disturbance in the immunoregulatory mechanism of the host was due to cyclophosphamide rather than to changes in tumor load, revealed that levels of AACs parallel disease progression in the initial stages of primary tumor growth but rapidly decrease to near-normal levels in the presence of heavy tumor burden. More... »

PAGES

15-18

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00294015

DOI

http://dx.doi.org/10.1007/bf00294015

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1020516611

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2028560


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adjuvants, Immunologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibody Formation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigen-Antibody Complex", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of, Illinois College of Medicine, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.185648.6", 
          "name": [
            "Division of Urology, Cook County Hospital, Chicago, Illinois, USA", 
            "University of, Illinois College of Medicine, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bhatti", 
        "givenName": "R.", 
        "id": "sg:person.01026264377.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026264377.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of, Illinois College of Medicine, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.185648.6", 
          "name": [
            "Division of Urology, Cook County Hospital, Chicago, Illinois, USA", 
            "University of, Illinois College of Medicine, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ray", 
        "givenName": "P.", 
        "id": "sg:person.01171331567.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171331567.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of, Illinois College of Medicine, Chicago, Illinois, USA", 
          "id": "http://www.grid.ac/institutes/grid.185648.6", 
          "name": [
            "Division of Urology, Cook County Hospital, Chicago, Illinois, USA", 
            "University of, Illinois College of Medicine, Chicago, Illinois, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bell", 
        "givenName": "N.", 
        "id": "sg:person.0647240120.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647240120.61"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf01951666", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016858399", 
          "https://doi.org/10.1007/bf01951666"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00736410", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034281087", 
          "https://doi.org/10.1007/bf00736410"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1978.190", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008054481", 
          "https://doi.org/10.1038/bjc.1978.190"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1991-02", 
    "datePublishedReg": "1991-02-01", 
    "description": "The object of the present investigations was delineation of the exclusive effects of cyclophosphamide (Cytoxan) on host humoral response to tumor, as evaluated by the level of circulating antigen/antibody complexes (AACs), which may reflect the chemo-responsiveness of hosts and provide a rationale for new therapeutic strategies. Our data, recorded in CopenhagenxFischer rats bearing Dunning's R-3327 Mat Ly-Lu adenocarcinoma of the prostate, show no modulatory effect of cyclophosphamide at 10 mg/kg, a nonspecific immunosuppressive effect at 30 mg/kg, and a definite immunostimulatory effect on host humoral immunity at 100 mg/kg. Sequential determination of AAC levels at different stages of tumor growth, i.e. from the primary to the metastatic stage, performed with the original purpose of demonstrating that any disturbance in the immunoregulatory mechanism of the host was due to cyclophosphamide rather than to changes in tumor load, revealed that levels of AACs parallel disease progression in the initial stages of primary tumor growth but rapidly decrease to near-normal levels in the presence of heavy tumor burden.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf00294015", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1016657", 
        "issn": [
          "2194-7228", 
          "2194-7236"
        ], 
        "name": "Urolithiasis", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "keywords": [
      "antigen/antibody complexes", 
      "host humoral immunity", 
      "humoral immunity", 
      "tumor growth", 
      "nonspecific immunosuppressive effect", 
      "heavy tumor burden", 
      "near-normal levels", 
      "primary tumor growth", 
      "host humoral response", 
      "new therapeutic strategies", 
      "immunoregulatory mechanisms", 
      "tumor burden", 
      "tumor load", 
      "humoral response", 
      "immunosuppressive effects", 
      "immunomodulatory effects", 
      "disease progression", 
      "therapeutic strategies", 
      "metastatic stage", 
      "immunostimulatory effects", 
      "modulatory effects", 
      "cyclophosphamide", 
      "adenocarcinoma", 
      "prostate", 
      "antibody complexes", 
      "immunity", 
      "levels", 
      "rats", 
      "tumors", 
      "exclusive effect", 
      "progression", 
      "effect", 
      "burden", 
      "present investigation", 
      "different stages", 
      "stage", 
      "primary", 
      "AAC levels", 
      "host", 
      "response", 
      "sequential determination", 
      "rationale", 
      "delineation", 
      "disturbances", 
      "changes", 
      "presence", 
      "growth", 
      "mechanism", 
      "purpose", 
      "data", 
      "strategies", 
      "investigation", 
      "initial stage", 
      "load", 
      "original purpose", 
      "complexes", 
      "determination", 
      "objects", 
      "CopenhagenxFischer rats", 
      "Dunning's R-3327 Mat Ly-Lu adenocarcinoma", 
      "'s R-3327 Mat Ly-Lu adenocarcinoma", 
      "Mat Ly-Lu adenocarcinoma", 
      "Ly-Lu adenocarcinoma", 
      "definite immunostimulatory effect", 
      "levels of AACs", 
      "Dunning's R-3327 adenocarcinoma", 
      "'s R-3327 adenocarcinoma"
    ], 
    "name": "Immunomodulatory effect of cyclophosphamide on host humoral immunity in Dunning's R-3327 adenocarcinoma of the prostate", 
    "pagination": "15-18", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1020516611"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00294015"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2028560"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00294015", 
      "https://app.dimensions.ai/details/publication/pub.1020516611"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:06", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_235.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf00294015"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00294015'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00294015'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00294015'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00294015'


 

This table displays all metadata directly associated to this object as RDF triples.

192 TRIPLES      22 PREDICATES      106 URIs      95 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00294015 schema:about N152639d0f47b499aa031ad11aadcbe9b
2 N1d3dbbf1a9a74844bfbe214e6236373e
3 N6368507d13774acfad0e0953ce82e181
4 N657a35792b824b7989e84727c5dd3612
5 N8531239b24fa4642861604098ec3c5e2
6 Na58850f6bd2140e4a3e85a5ce0887207
7 Nec4381f771014580bc6dfc4f48359efa
8 Nf76fad66828640c0bb2d9b0c1068400d
9 Nfe01b7470a9d4072a49525770d248ba6
10 anzsrc-for:11
11 anzsrc-for:1103
12 schema:author Neff4e95e27e04da7ac6dcc9c30c6a51a
13 schema:citation sg:pub.10.1007/bf00736410
14 sg:pub.10.1007/bf01951666
15 sg:pub.10.1038/bjc.1978.190
16 schema:datePublished 1991-02
17 schema:datePublishedReg 1991-02-01
18 schema:description The object of the present investigations was delineation of the exclusive effects of cyclophosphamide (Cytoxan) on host humoral response to tumor, as evaluated by the level of circulating antigen/antibody complexes (AACs), which may reflect the chemo-responsiveness of hosts and provide a rationale for new therapeutic strategies. Our data, recorded in CopenhagenxFischer rats bearing Dunning's R-3327 Mat Ly-Lu adenocarcinoma of the prostate, show no modulatory effect of cyclophosphamide at 10 mg/kg, a nonspecific immunosuppressive effect at 30 mg/kg, and a definite immunostimulatory effect on host humoral immunity at 100 mg/kg. Sequential determination of AAC levels at different stages of tumor growth, i.e. from the primary to the metastatic stage, performed with the original purpose of demonstrating that any disturbance in the immunoregulatory mechanism of the host was due to cyclophosphamide rather than to changes in tumor load, revealed that levels of AACs parallel disease progression in the initial stages of primary tumor growth but rapidly decrease to near-normal levels in the presence of heavy tumor burden.
19 schema:genre article
20 schema:inLanguage en
21 schema:isAccessibleForFree false
22 schema:isPartOf N0a29b19ec5a54ff4bba8a7f50e0af741
23 N4d2eecad62bb477f8b185e1c95889b3d
24 sg:journal.1016657
25 schema:keywords 's R-3327 Mat Ly-Lu adenocarcinoma
26 's R-3327 adenocarcinoma
27 AAC levels
28 CopenhagenxFischer rats
29 Dunning's R-3327 Mat Ly-Lu adenocarcinoma
30 Dunning's R-3327 adenocarcinoma
31 Ly-Lu adenocarcinoma
32 Mat Ly-Lu adenocarcinoma
33 adenocarcinoma
34 antibody complexes
35 antigen/antibody complexes
36 burden
37 changes
38 complexes
39 cyclophosphamide
40 data
41 definite immunostimulatory effect
42 delineation
43 determination
44 different stages
45 disease progression
46 disturbances
47 effect
48 exclusive effect
49 growth
50 heavy tumor burden
51 host
52 host humoral immunity
53 host humoral response
54 humoral immunity
55 humoral response
56 immunity
57 immunomodulatory effects
58 immunoregulatory mechanisms
59 immunostimulatory effects
60 immunosuppressive effects
61 initial stage
62 investigation
63 levels
64 levels of AACs
65 load
66 mechanism
67 metastatic stage
68 modulatory effects
69 near-normal levels
70 new therapeutic strategies
71 nonspecific immunosuppressive effect
72 objects
73 original purpose
74 presence
75 present investigation
76 primary
77 primary tumor growth
78 progression
79 prostate
80 purpose
81 rationale
82 rats
83 response
84 sequential determination
85 stage
86 strategies
87 therapeutic strategies
88 tumor burden
89 tumor growth
90 tumor load
91 tumors
92 schema:name Immunomodulatory effect of cyclophosphamide on host humoral immunity in Dunning's R-3327 adenocarcinoma of the prostate
93 schema:pagination 15-18
94 schema:productId N01f4b77c1d334b29ac96e3fe5c2cdb85
95 N4b397fd8078946b58b7549b131525d90
96 Ned1fb01a656f46ba86735ed1896fb85d
97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020516611
98 https://doi.org/10.1007/bf00294015
99 schema:sdDatePublished 2022-01-01T18:06
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher Na42177dd7eff437fa00fd2bebc3795c7
102 schema:url https://doi.org/10.1007/bf00294015
103 sgo:license sg:explorer/license/
104 sgo:sdDataset articles
105 rdf:type schema:ScholarlyArticle
106 N01f4b77c1d334b29ac96e3fe5c2cdb85 schema:name dimensions_id
107 schema:value pub.1020516611
108 rdf:type schema:PropertyValue
109 N0a29b19ec5a54ff4bba8a7f50e0af741 schema:volumeNumber 19
110 rdf:type schema:PublicationVolume
111 N152639d0f47b499aa031ad11aadcbe9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Cyclophosphamide
113 rdf:type schema:DefinedTerm
114 N1d3dbbf1a9a74844bfbe214e6236373e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Male
116 rdf:type schema:DefinedTerm
117 N2d2fa28e6fc143b2ae7aa1095d71ec77 rdf:first sg:person.01171331567.29
118 rdf:rest N3f384bf9422d4e9e99234291d9aa706b
119 N3f384bf9422d4e9e99234291d9aa706b rdf:first sg:person.0647240120.61
120 rdf:rest rdf:nil
121 N4b397fd8078946b58b7549b131525d90 schema:name doi
122 schema:value 10.1007/bf00294015
123 rdf:type schema:PropertyValue
124 N4d2eecad62bb477f8b185e1c95889b3d schema:issueNumber 1
125 rdf:type schema:PublicationIssue
126 N6368507d13774acfad0e0953ce82e181 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Adjuvants, Immunologic
128 rdf:type schema:DefinedTerm
129 N657a35792b824b7989e84727c5dd3612 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Animals
131 rdf:type schema:DefinedTerm
132 N8531239b24fa4642861604098ec3c5e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Antigen-Antibody Complex
134 rdf:type schema:DefinedTerm
135 Na42177dd7eff437fa00fd2bebc3795c7 schema:name Springer Nature - SN SciGraph project
136 rdf:type schema:Organization
137 Na58850f6bd2140e4a3e85a5ce0887207 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Rats
139 rdf:type schema:DefinedTerm
140 Nec4381f771014580bc6dfc4f48359efa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Prostatic Neoplasms
142 rdf:type schema:DefinedTerm
143 Ned1fb01a656f46ba86735ed1896fb85d schema:name pubmed_id
144 schema:value 2028560
145 rdf:type schema:PropertyValue
146 Neff4e95e27e04da7ac6dcc9c30c6a51a rdf:first sg:person.01026264377.25
147 rdf:rest N2d2fa28e6fc143b2ae7aa1095d71ec77
148 Nf76fad66828640c0bb2d9b0c1068400d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Antibody Formation
150 rdf:type schema:DefinedTerm
151 Nfe01b7470a9d4072a49525770d248ba6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Adenocarcinoma
153 rdf:type schema:DefinedTerm
154 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
155 schema:name Medical and Health Sciences
156 rdf:type schema:DefinedTerm
157 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
158 schema:name Clinical Sciences
159 rdf:type schema:DefinedTerm
160 sg:journal.1016657 schema:issn 2194-7228
161 2194-7236
162 schema:name Urolithiasis
163 schema:publisher Springer Nature
164 rdf:type schema:Periodical
165 sg:person.01026264377.25 schema:affiliation grid-institutes:grid.185648.6
166 schema:familyName Bhatti
167 schema:givenName R.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026264377.25
169 rdf:type schema:Person
170 sg:person.01171331567.29 schema:affiliation grid-institutes:grid.185648.6
171 schema:familyName Ray
172 schema:givenName P.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171331567.29
174 rdf:type schema:Person
175 sg:person.0647240120.61 schema:affiliation grid-institutes:grid.185648.6
176 schema:familyName Bell
177 schema:givenName N.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647240120.61
179 rdf:type schema:Person
180 sg:pub.10.1007/bf00736410 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034281087
181 https://doi.org/10.1007/bf00736410
182 rdf:type schema:CreativeWork
183 sg:pub.10.1007/bf01951666 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016858399
184 https://doi.org/10.1007/bf01951666
185 rdf:type schema:CreativeWork
186 sg:pub.10.1038/bjc.1978.190 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008054481
187 https://doi.org/10.1038/bjc.1978.190
188 rdf:type schema:CreativeWork
189 grid-institutes:grid.185648.6 schema:alternateName University of, Illinois College of Medicine, Chicago, Illinois, USA
190 schema:name Division of Urology, Cook County Hospital, Chicago, Illinois, USA
191 University of, Illinois College of Medicine, Chicago, Illinois, USA
192 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...